CTLA4 and melanoma: Given TRM widely express CTLA-4, PD-1 and LAG-3, which are inhibited by immune checkpoint inhibitors such as ipilimumab, nivolumab, pembrolizumab and relatlimab provides a strong biological rationale this CD8 subset is critical in facilitating anti-tumor responses in melanoma.